Skip to main content

Table 6 Plasma pharmacokinetic parameters for PR-104A metabolites, cycle 1 day 1

From: A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

   Cmax(μM) AUC (μM h) t1/2(h)
Dose-level (mg/m 2 ) n PR-104G PR-104H PR-104M PR-104S1 PR-104G PR-104H PR-104M PR-104S1 PR-104G PR-104H PR-104M PR-104S1
135 2 1.66 0.66 0.05 0.06 1.67 0.79 0.08 0.10 0.25 0.48 0.53 0.76
270 6 3.02 (2.12) 0.68 (0.29) 0.06 (0.02) 0.14 (0.09) 3.96 (3.81) 0.81 (0.37) 0.11 (0.05) 0.25 (0.17) 0.40 (0.22) 0.51 (0.12) 0.88 (0.43) 1.09 (0.51)
540 6 11.27 (8.07) 0.49 (0.17) 0.07 (0.02) 0.20 (0.08) 13.85 (12.01) 0.63 (0.26) 0.11 (0.04) 0.29 (0.13) 0.38 (0.14) 0.41 (0.12) 0.56 (0.15) 0.59 (0.23)
675 7 8.71 (4.52) 0.51 (0.27) 0.08 (0.05) 0.36 (0.25) 11.9 (7.4) 0.71 (0.32) 0.13 (0.06) 0.49 (0.45) 0.49 (0.17) 0.74 (0.37) 0.75 (0.28) 0.68 (0.12)
900 4 7.81 (3.92) 0.39 (0.16) 0.07 (0.03) 0.31 (0.13) 11.19 (6.54) 0.69 (0.26) 0.16 (0.08) 0.64 (0.25) 0.68 (0.18) 0.85 (0.09) 0.88 (0.11) 0.79 (0.15)
  1. Values are the mean (SD)